SCHEMBL19691007

SCHEMBL19691007

Cc1cc(C)n(-c2nc(Cl)cc(CC=O)n2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.63
ALOX15 P16050 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
LMNA P02545 2/20 0.41
CYP2C19 P33261 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 2/20 0.40
HSD17B10 Q99714 1/20 0.40
BCL6 P41182 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
PTPN7 P35236 1/20 0.40
CREBBP Q92793 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KCNN3 Q9UGI6 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1936057 0.81 HTT (0.86) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL11174391 0.78 HTT (1.00) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL19687417 0.75 HTT (0.75) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL25318412 0.75 HTT (0.46) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL2812766 0.74 HTT (0.73) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL19690985 0.74 HTT (0.67) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL11178856 0.72 HTT (0.65) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL4138642 0.72 HTT (0.68) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL21144202 0.71 HTT (0.68) HTTALOX15SMN1; SMN2KMT2ACYP1A2
SCHEMBL4140825 0.71 HTT (0.68) HTTALOX15SMN1; SMN2KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 HTT 1113/4885ALOX15 2955/4885SMN1; SMN2 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.